Salvador Cabrera Figueroa

Impact of Pharmacogenetics on CNS Side Effects Related to Efavirenz

Almudena Sánchez Martín, Salvador Cabrera Figueroa, Raquel Cruz et al. · Pharmacogenomics · 2013 · 35 citations · Full text

Dose Reduction of Efavirenz: An Observational Study Describing Cost–Effectiveness, Pharmacokinetics and Pharmacogenetics

Almudena Sánchez Martín, Alicia Iglesias Gómez, Belén García‐Berrocal et al. · Pharmacogenomics · 2014 · 29 citations

Long-Term Efficacy and Safety of Efavirenz Dose Reduction to 200 mg Once Daily in a Caucasian Patient with HIV

Salvador Cabrera Figueroa, Alicia Iglesias Gómez, Almudena Sánchez Martín et al. · Clinical Drug Investigation · 2010 · 17 citations

Long-term Efficacy, Treatment And Prevention, Caucasian Patient +8

The Convergence of Therapeutic Drug Monitoring and Pharmacogenetic Testing to Optimize Efavirenz Therapy

Salvador Cabrera Figueroa, María Fernández de Gatta, L. Hernández-García et al. · Therapeutic Drug Monitoring · 2010 · 16 citations

Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

Almudena Sánchez-Martín, Salvador Cabrera Figueroa, Raquel Cruz et al. · Drug Metabolism and Pharmacokinetics · 2016 · 12 citations

Cyp2b6 Polymorphisms, Neurovirology, Medicine +7